vidarabine has been researched along with orlistat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Debey, S; Hallek, M; Kofler, D; Königs, S; Pallasch, CP; Schultze, JL; Schulz, A; Schwamb, J; Ultsch, A; Wendtner, CM | 1 |
3 other study(ies) available for vidarabine and orlistat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
Topics: Apoptosis; B-Lymphocytes; Drug Screening Assays, Antitumor; Drug Synergism; Fatty Acids, Nonesterified; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lipid Metabolism; Lipoprotein Lipase; Multigene Family; Neoplasm Proteins; Orlistat; Phospholipases; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Vidarabine | 2008 |